PLRX

0.59514.02%
RD

Rik Derynck

Scientific Founder & Member of Scientific Advisory Board

Dr. Rik Derynck, Ph.D. is a Scientific Founder of Pliant Therapeutics, Inc. since 2015 and is its Member of Scientific Advisory Board since January 5, 2017. Dr. Derynck serves as Scientific Advisor at Applied Protein Sciences, LLC. In 1981, Dr. Derynck moved to the San Francisco Bay Area and joined Genentech, one of the first biotech companies. As a scientist in the lab of Dr. David Goeddel, he continued his research on interferon and also initiated a project that led to the molecular characterization of tumor necrosis factor (TNF). He subsequently initiated research aimed at the molecular characterization of transforming growth factor (TGF), whose controversial activity had just been identified in the secreted medium of some tumor cells, where it had the ability to induce reversible transformation of fibroblasts in culture. In 1991, he moved his lab to UCSF. He is a Professor and Vice Chair in the Department of Cell and Tissue Biology and Professor in the Department of Anatomy. He serves as a Director of the Program in Craniofacial and Mesenchymal Biology and Co-Director of the UCSF Institute for Regeneration Medicine. After purifying some restriction enzymes of his own and developing a 2-D system to separate DNA fragments, he cloned the cDNA for human fibroblast interferon, now known as interferon-beta. He received his Dr. Sc. degree in 1981. Dr. Derynck received his undergraduate education and Lic. Sc. in Zoology at the University of Leuven, Belgium. He then moved to the University of Ghent, Belgium, to pursue his Dr. Sc. training under the mentorship of Dr. Walter Fiers. Dr. Derynck holds a Ph.D. degree from the University of Ghent, Belgium, for the cDNA cloning and expression of fibroblast interferon (interferon-), which provided the basis for the clinical development of this interferon by Biogen.

Positions